Exploring a new mechanism to fund the timely execution of deprioritized trials
Introduction: Some biopharma companies have built pipelines that offer more development opportunities than their resources allow them to pursue. Promising clinical trials may be moved down the priority list and their execution delayed resulting in decline of asset value against a fixed patent expiration date.
One potential solution is to package complementary trials and bring them into collaboration with the investor, CRO or other organizations and fund the execution of these trials outside the biopharma company. The potential advantages of this approach are four-fold: the trials supporting asset development will be delivered, investors have an opportunity to generate a high return, CROs expand their revenue base and additional patient populations may benefit.
Released: March 2017
Download File ADL_Funding_lower_priority_clinical_trials.pdf (.PDF, 229 Kb)
« previous report | next report »